
pharma.be, the umbrella organization of 125 innovative pharmaceutical companies active in Belgium, regrets that the Constitutional Court has not taken an explicit decision to annul the discriminatory “clawback” measure in the pharmaceutical budget.
Under a new law passed in parliament in April 2020, only innovative pharmaceutical companies were required to reimburse drug budget overruns in 2020, while other manufacturers, including generic drug manufacturers, also contribute to the growth and were exempt from potential overruns.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze